BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

On December 6, 2021, BridgeBio Pharma (Nasdaq: BBIO) granted restricted stock units totaling 12,073 shares to nine new employees under its 2019 Inducement Equity Plan. This grant complies with Nasdaq Listing Rule 5635(c)(4) and was designed to incentivize employees joining the company. Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases and cancers, with a pipeline of over 30 programs and a goal of delivering its first two approved therapies.

Positive

• Granting restricted stock units incentivizes new talent, potentially enhancing operational capabilities.
• BridgeBio's robust pipeline includes over 30 development programs, indicating strong future growth prospects.

Negative

• None.

PALO ALTO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 6, 2021, the compensation committee of BridgeBio’s board of directors granted nine new employees restricted stock units for an aggregate of 12,073 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019.

About BridgeBio
BridgeBio Pharma (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company’s first two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.

Media Contact
Grace Rauh
Grace.rauh@bridgebio.com
(917) 232-5478

Source: BridgeBio Pharma, Inc.

 

FAQ

What did BridgeBio Pharma announce on December 6, 2021?

BridgeBio Pharma announced the granting of restricted stock units totaling 12,073 shares to nine new employees.

How many shares were granted by BridgeBio Pharma?

A total of 12,073 shares were granted to nine new employees.

What is the purpose of restricted stock units granted by BridgeBio?

The restricted stock units are intended as an inducement for new employees as part of the company's hiring strategy.

Under which plan were the restricted stock units granted?

The restricted stock units were granted under BridgeBio’s 2019 Inducement Equity Plan.

What is the stock symbol for BridgeBio Pharma?

The stock symbol for BridgeBio Pharma is BBIO.